Barinthus Biotherapeutics plc (BRNS) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
UNIT 6-10, ZEUS BUILDING DIDCOT, OX11 0DF |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2024 MRQ | 12/31/2023 | 12/31/2022 | 12/31/2021 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments | 142,090 | 194,385 | 214,054 | |||
| Cash and cash equivalents | 142,090 | 194,385 | 214,054 | |||
| Receivables | 3,031 | 5,847 | 725 | |||
| Prepaid expense | 5,402 | 5,887 | 4,612 | |||
| Contract with customer, asset, after allowance for credit loss | ||||||
| Other current assets | 1,474 | 563 | 995 | |||
| Other undisclosed current assets | 4,908 | 6,359 | 6,379 | |||
| Total current assets: | 156,905 | 213,041 | 226,765 | |||
| Noncurrent Assets | ||||||
| Operating lease, right-of-use asset | 7,581 | 7,753 | 7,257 | |||
| Property, plant and equipment | 11,821 | 7,957 | 1,829 | |||
| Intangible assets, net (including goodwill) | 37,317 | 40,478 | 44,060 | |||
| Goodwill | 12,209 | 12,209 | 12,630 | |||
| Intangible assets, net (excluding goodwill) | 25,108 | 28,269 | 31,430 | |||
| Other undisclosed noncurrent assets | 882 | 976 | 804 | |||
| Total noncurrent assets: | 57,601 | 57,164 | 53,950 | |||
| TOTAL ASSETS: | 214,506 | 270,205 | 280,715 | |||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities | 6,810 | 8,812 | 8,505 | |||
| Employee-related liabilities | ✕ | ✕ | 2,862 | 2,496 | ||
| Accounts payable | 1,601 | 3,748 | 2,419 | |||
| Accrued liabilities | 5,209 | 2,202 | 3,590 | |||
| Deferred revenue | 182 | |||||
| Debt | 159 | |||||
| Other undisclosed current liabilities | 5,788 | 3,430 | 2,312 | |||
| Total current liabilities: | 12,598 | 12,242 | 11,158 | |||
| Noncurrent Liabilities | ||||||
| Long-term debt and lease obligation: | 6,540 | |||||
| Liabilities, other than long-term debt | 14,339 | 11,016 | 2,371 | |||
| Deferred income tax liabilities | ||||||
| Other liabilities | 1,325 | 965 | ||||
| Operating lease, liability | 11,191 | 8,340 | 6,540 | |||
| Business combination, contingent consideration, liability | 1,823 | 1,711 | 2,371 | |||
| Other undisclosed noncurrent liabilities | 574 | 3,746 | 8,084 | |||
| Total noncurrent liabilities: | 14,913 | 14,762 | 16,995 | |||
| Total liabilities: | 27,511 | 27,004 | 28,153 | |||
| Equity | ||||||
| Equity, attributable to parent, including: | 186,784 | 242,896 | 252,031 | |||
| Common stock | 1 | 1 | 1 | |||
| Additional paid in capital | 386,602 | 379,504 | 369,103 | |||
| Accumulated other comprehensive loss | (23,315) | (33,460) | (8,488) | |||
| Accumulated deficit | (176,590) | (103,243) | (108,585) | |||
| Other undisclosed equity, attributable to parent | 86 | 94 | ||||
| Equity, attributable to noncontrolling interest | 211 | 305 | 437 | |||
| Other undisclosed equity | 94 | |||||
| Total equity: | 186,995 | 243,201 | 252,562 | |||
| TOTAL LIABILITIES AND EQUITY: | 214,506 | 270,205 | 280,715 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|---|
| Revenues | 802 | 44,703 | 268 | ||
| Gross profit: | 802 | 44,703 | 268 | ||
| Operating expenses | (84,716) | (48,744) | (45,489) | ||
| Other undisclosed operating income | |||||
| Operating loss: | (83,914) | (4,041) | (45,221) | ||
| Nonoperating income (expense) | 7,392 | 4,891 | (5,919) | ||
| Investment income, nonoperating | 2,877 | 3,103 | 2 | ||
| Interest and debt expense | (28) | (19) | (16,457) | ||
| Income (loss) from continuing operations before equity method investments, income taxes: | (76,550) | 831 | (67,597) | ||
| Other undisclosed income from continuing operations before income taxes | 28 | 19 | |||
| Income (loss) from continuing operations before income taxes: | (76,522) | 850 | (67,597) | ||
| Income tax benefit | 3,075 | 4,471 | 28 | ||
| Income (loss) from continuing operations: | (73,447) | 5,321 | (67,569) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (67,569) | |
| Other undisclosed net income | 16,457 | ||||
| Net income (loss): | (73,447) | 5,321 | (51,112) | ||
| Net income attributable to noncontrolling interest | 100 | 21 | 247 | ||
| Net income (loss) available to common stockholders, diluted: | (73,347) | 5,342 | (50,865) | ||
Comprehensive Income ($ in thousands)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|---|
| Net income (loss): | (73,447) | 5,321 | (51,112) | ||
| Other undisclosed comprehensive income (loss) | 10,151 | (25,083) | (7,248) | ||
| Comprehensive loss: | (63,296) | (19,762) | (58,360) | ||
| Comprehensive income, net of tax, attributable to noncontrolling interest | 94 | 132 | 250 | ||
| Comprehensive loss, net of tax, attributable to parent: | (63,202) | (19,630) | (58,110) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.